Abstract Number: 2384 • 2012 ACR/ARHP Annual Meeting
Giant Cell Arteritis and Cardiovascular Events in the French Apogee Cohort. A Population-Based Study Using the French Health Insurance System Database
Background/Purpose: The risk of cardiovascular events (CVE) during giant cell arteritis (GCA) has rarely been quantified in population-based studies. Our objective was to quantify the…Abstract Number: 2345 • 2012 ACR/ARHP Annual Meeting
HRES-1/RAB4-Mediated Loss of DRP1 Inhibits Mitophagy, Promotes Accumulation of Mitochondria and Serves As Target for Treatment in SLE
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) exhibit accumulation of mitochondria and activation of the mammalian target of rapamycin (mTOR). Although mTOR…Abstract Number: 2346 • 2012 ACR/ARHP Annual Meeting
MHC II-Independent Regulation of Intestinal Tregs
Background/Purpose: Regulatory T cells (Tregs) are critical to prevent autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis. Like all CD4+ T cells, CD4+…Abstract Number: 2347 • 2012 ACR/ARHP Annual Meeting
Specificity of the New American College of Rheumatology/European League Against Rheumatism Classification Criteria for Polymyalgia Rheumatica in Comparison with the Former Ones : A Single Centre Study
Background/Purpose: To evaluate the specificity of the new ACR/EULAR classification criteria for PMR in a consecutive series of outpatients attending an early arthritis clinic (EAC).…Abstract Number: 2348 • 2012 ACR/ARHP Annual Meeting
Plasma Fibrinogen Better Identifies Persistent Disease Activity in Polymyalgia Rheumatica Than Either ESR or CRP
Background/Purpose: In PMR careful tailoring of the glucocorticoid dosage to the patients needs is crucial to avoid the risk of treatment-related adverse effects and the…Abstract Number: 2349 • 2012 ACR/ARHP Annual Meeting
Corticosterois Therapy Restaured Treg/Th17 Balance in Patients with Polimyalgia Rheumatica
Background/Purpose: To characterize the levels of circulating T regulatory cells (Tregs) and Th17 cells in polymyalgia rheumatica (PMR). Methods: The study included 46 patients with…Abstract Number: 2350 • 2012 ACR/ARHP Annual Meeting
Similarities Exceeds Differences in the Pattern of Joint and Vascular Positron Emission/Computed Tomography Uptake in Polymyalgia Rheumatica and Giant Cell Arteritis
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are two frequent overlapping diseases. The purpose of this work is to examine the relationship between…Abstract Number: 2351 • 2012 ACR/ARHP Annual Meeting
Correlation Between Hypoechoic Halo of the Temporal Arteries and Clinical, Laboratory, and Temporal Artery Biopsy Findings in Patients with Giant Cell Arteritis
Background/Purpose: The presence of a hypoechoic halo of the temporal arteries on Color-Doppler sonography (CDS) has high specificity and acceptable sensitivity for the diagnosis of…Abstract Number: 2352 • 2012 ACR/ARHP Annual Meeting
Temporal Artery Biopsy Culture in Tridimensional Matrix. an in Vitro Model for Functional Studies in Giant-Cell Arteritis
Background/Purpose: GCA is the most frequent systemic vasculitis in Europe and North America. In spite of the initial response to glucocorticoid treatment more than 60%…Abstract Number: 2353 • 2012 ACR/ARHP Annual Meeting
TLR2 Activation by Acute Serum Amyloid A Induces Pro-Inflammatory Mechanisms in a Novel Ex Vivo Temporal Artery Explant Culture/Model of Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary vasculitis. The pathogenesis of this disease is characterised by disregulated angiogenesis and inflammatory…Abstract Number: 2354 • 2012 ACR/ARHP Annual Meeting
The Prevalence of Low Bone Mineral Density in Patients with New Onset Giant Cell Arteritis. Do They Get Appropriate Bone Protective Treatment?
Background/Purpose: Giant cell arteritis (GCA) is a common form of vasculitis mainly affecting individuals older than 50 years with a mean onset age of 69…Abstract Number: 2355 • 2012 ACR/ARHP Annual Meeting
Increase in Duration and Cumulative Dose of Glucocorticoid Therapy in Recent Decades: Observations From a Population-Based Cohort of Patients with Giant Cell Arteritis
Background/Purpose: Systemic glucocorticoid (GC) therapy is the first line treatment for giant cell arteritis (GCA). Patients with GCA are often counseled that therapy will be…Abstract Number: 2356 • 2012 ACR/ARHP Annual Meeting
Visual Manifestations in Giant Cell Arteritis : Trend Over Five Decades
Background/Purpose: Cranial ischemic complications, particularly permanent visual loss, are catastrophic complications of giant cell arteritis (GCA). Corticosteroids have been used to decrease the risk of…Abstract Number: 2357 • 2012 ACR/ARHP Annual Meeting
Relapses in Patients with Giant-Cell Arteritis: Prevalence, Characteristics and Associated Clinical Findings in a Prospectively Followed Cohort of 106 Patients
Background/Purpose: In spite of the satisfactory initial response to glucocorticoid treatment, patients with giant cell arteritis (GCA) frequently experience relapses during follow-up. The objectives of…Abstract Number: 2358 • 2012 ACR/ARHP Annual Meeting
Large Vessel Giant Cell Arteritis: A Cohort Study
Background/Purpose: A subset of patients with giant cell arteritis (GCA) has large vessel (LV) involvement. We sought to identify baseline variables that distinguish patients with…
ACR Meeting Abstracts